Welcome to our dedicated page for Schrodinger news (Ticker: $SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Schrodinger's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Schrodinger's position in the market.
Schrödinger, Inc. (Nasdaq: SDGR) reported first-quarter 2024 financial results with total revenue of $36.6 million and software revenue of $33.4 million. The company announced FDA clearance of an IND application for SGR-3515, a Wee1/Myt1 Inhibitor. SGR-1505 and SGR-2921 Phase 1 data readouts are expected in late 2024 or 2025. Despite a decrease in total revenue from the first quarter of 2023, Schrödinger remains optimistic about the growing interest in computational drug discovery and revenue growth opportunities.